Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II / III trial of JCOG1008
Cancer Medicine · 2024
DOI: 10.1002/cam4.70235 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yoshinori Imamura und 20 weiteren Autor:innen. Beteiligte Einrichtung: Kobe University Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Cisplatin, Acute Kidney Injury, Head and Neck Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center Research and Development Funds, Grant-in-Aid for Clinical Cancer Research (H23-009 and H26-052) from the Ministry of Health, Labor and Welfare of Japan, Japan Agency for Medical Research and…, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m 2 ) was non‐inferior to 3‐weekly cisplatin (100 mg/m 2 ) for postoperative high‐risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose‐limiting toxicity effect of cisplatin, affects overall survival (OS).
Methods
We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy. AKI was defined based on AKI Network criteria (serum creatinine increase of ≥0.3 mg/dL or ≥1.5‐fold [≥ stage I]) within 30 days after completing chemoradiotherapy. OS in the two arms was compared according to AKI development using the log‐rank test.
Results
The total incidence of AKI was lower in the weekly arm than in the 3‐weekly arm (38/122 [31.1%] vs. 56/129 [43.4%]). Additionally, stage II/III AKI occurred less frequently in the weekly arm than in the 3‐weekly arm (8/122 [6.6%] vs. 19/129 [14.7%]). Cisplatin doses were similar in the weekly arm for patients with and without AKI (median, 238.6 mg/m 2 vs. 239.2 mg/m 2 ; p = 0.94), but lower in the 3‐weekly arm for those who developed AKI (median, 276.3 mg/m 2 vs. 297.4 mg/m 2 ; p = 0.007). In the weekly arm, there was no difference in OS between patients with and without AKI (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.53 to 2.10). However, in the 3‐weekly arm, patients with AKI had poorer OS than those without AKI (HR, 1.83; 95% CI, 1.04 to 3.21).
Conclusions
In this supplementary analysis of JCOG1008 data, AKI impacted the OS of patients with head and neck cancer undergoing postoperative chemoradiotherapy in the 3‐weekly arm but not in the weekly arm. Our results further endorse the utilization of weekly cisplatin at 40 mg/m 2 in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kobe University Hospital, Kobe, Japan.
- National Cancer Center Hospital East, Kashiwa, Japan.
- Aichi Cancer Center Hospital, Nagoya, Japan.
- Jichi Medical University Hospital, Shimotsuke, Japan.
- Miyagi Cancer Center, Natori, Japan.
- Cancer Institute Hospital, Tokyo, Japan.
ORCID-Profile: Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma
Förderung
- National Cancer Center Research and Development Funds
- Grant-in-Aid for Clinical Cancer Research (H23-009 and H26-052) from the Ministry of Health, Labor and Welfare of Japan, Japan Agency for Medical Research and…
- Japan Agency for Medical Research and Development
Zitieren
APA
Imamura, Y., Kiyota, N., Tahara, M., Kodaira, T., Hayashi, R., Nishino, H., Asada, Y., Mitani, H., Iwae, S., Nishio, N., Onozawa, Y., Hanai, N., Ohkoshi, A., Hara, H., Monden, N., Nagaoka, M., Minami, S., Kitabayashi, R., Sasaki, K., …, & Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG‐HNCSG) (2024). Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II / III trial of JCOG1008. Cancer Medicine. https://doi.org/10.1002/cam4.70235
Vancouver
Imamura Y, Kiyota N, Tahara M, Kodaira T, Hayashi R, Nishino H, et al. Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II / III trial of JCOG1008. Cancer Medicine. 2024. doi:10.1002/cam4.70235
BibTeX
@article{Imamura2024,
author = {Imamura, Yoshinori and Kiyota, Naomi and Tahara, Makoto and Kodaira, Takeshi and Hayashi, Ryuichi and Nishino, Hiroshi and Asada, Yukinori and Mitani, Hiroki and Iwae, Shigemichi and Nishio, Naoki and Onozawa, Yusuke and Hanai, Nobuhiro and Ohkoshi, Akira and Hara, Hiroki and Monden, Nobuya and Nagaoka, Masato and Minami, Shujiro and Kitabayashi, Ryo and Sasaki, Keita and Homma, Akihiro and Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG‐HNCSG), Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG‐HNCSG)},
title = {Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II / III trial of JCOG1008},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70235}
}
EUVIMED